Researchers have isolated two immune system responses to an HIV vaccine that may indicate whether the vaccine will protect certain individuals, CNN reports. The research is the result of a Phase III clinical trial, RV-144, which involved more than 16,000 healthy adults in Thailand. Results showed that the vaccine was 31 percent effective, and investigators deemed it “modestly protective.” After two years of analyzing the data, researchers found that the vaccine produced two types of immune responses: one that boosted the vaccine's efficacy and one that led to the same infection rate as the placebo. Researchers say the results will be helpful in the design of future clinical trials. The new data were released at the annual AIDS vaccine conference held this year in Bangkok.

To read the CNN article, click here.